Recorded Presentation from the New NCCN Guidelines for Pediatric Cancers: Key Considerations for the Management of Pediatric Hodgkin Lymphoma (JA copy)
Pediatric patients with Hodgkin lymphoma are susceptible to developing late effects due to early and cumulative exposure to chemotherapy, including alkylating agents and anthracyclines, and radiotherapy. In this regard, contemporary clinical trials aim to develop strategies that minimize the effects of treatment-related toxicities, by improving risk stratification and developing less-toxic therapies. The NCCN Guidelines for pediatric Hodgkin lymphoma were created to help define optimal clinical care for these patients. Continuing education on emerging developments in this arena will help ensure that clinicians are aware of how best to incorporate these strategies, which may enhance care and outcomes for patients with pediatric Hodgkin lymphoma.
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage pediatric patients with cancer.
Following this activity, participants should be able to:
- Summarize current risk stratification and response assessment for pediatric Hodgkin lymphoma.
- Identify treatment strategies that minimize toxicity in pediatric Hodgkin lymphoma.
- Describe emerging treatment strategies for pediatric Hodgkin lymphoma.
Jamie Flerlage, MD, MS
St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
Sarah H. Aldridge, MSN, CPNP-AC, RN
St. Jude Children's Research Hospital
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses no relevant financial relationships:
Sarah H. Aldridge, MSN, CPNP-AC, RN
The faculty listed below discloses the following relevant financial relationships:
Jamie Flerlage, MD, MS
Seattle Genetics, Inc.: Grant/Research Support
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Mike Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Ndiya Ogba, PhD; Jennifer L. Burns, BS
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-20-118-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until December 23, 2021. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing